002390 信邦制药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入4,565,356-5.35%6,460,8416,350,0266,471,8665,845,622
减:营业总成本4,276,861-4.34%6,029,9576,015,5746,003,7995,486,290
    其中:营业成本3,724,211-3.53%5,232,2655,133,0655,119,3714,593,544
               财务费用13,197-45.95%27,75338,97987,16682,748
               资产减值损失----(7,523)----(500)
公允价值变动收益------------
投资收益1,301-264.84%9,39737,4273,920(16,971)
    其中:对联营企业和合营企业的投资收益--------47--
营业利润267,244-21.36%385,033316,323451,510287,403
利润总额264,272-21.28%396,022313,394421,125267,456
减:所得税费用31,535-2.23%42,24945,13847,17046,881
净利润232,738-23.30%353,773268,255373,955220,575
减:非控股权益56,148-1.27%66,54043,881101,08647,054
股东净利润176,590-28.38%287,233224,374272,869173,521

市场价值指针
每股收益 (元) *0.093-27.01%0.1500.1200.1500.110
每股派息 (元) *0.030--0.0600.0600.060--
每股净资产 (元) *3.491-1.15%3.5253.5033.2652.950
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容